For the sentences you want to check

Dear reader,

These are the sources used in the letters. I'd start with the sentence that raised a question, then follow its link here. You don't need to read the whole list to ask about one finding.

A study, a product label and an FDA explanation do different jobs. The short notes below explain why each one is here. The source can answer a question about the research; it can't decide whether a medicine fits you.

Studies in people

• The diabetes trial called SUSTAIN 1. Semaglutide alone lowered HbA1c and body weight more than placebo in adults with type 2 diabetes at 30 weeks. HbA1c reflects average blood sugar over about three months. This is the source for the diabetes study amounts on the dose page.
• The weight-management trial called STEP 1. Participants didn't have diabetes; they had obesity, or overweight with a related health condition. Both groups had lifestyle support. The trial supplies the other injection amount discussed on the dose page.
• The heart-outcome trial called SELECT. Participants were adults aged 45 or older with established cardiovascular disease and a body mass index (BMI) of at least 27, without diabetes. Semaglutide reduced the combined risk of nonfatal heart attack, nonfatal stroke or death from cardiovascular causes compared with placebo. This combined outcome does not establish a separate reduction in each event. That population remains part of the finding.
• The STEP 1 follow-up after treatment ended. Adults previously assigned semaglutide regained about two-thirds of their earlier weight loss, on average, over the year after treatment and lifestyle support stopped. This was a subset of STEP 1 participants, with obesity, or overweight with a related health condition, without diabetes. The letters use this to open a question about ongoing care.

Side effects and how the medicine works

• Digestive tolerability in weight-management trials. This pooled analysis describes nausea, vomiting, diarrhea and constipation. Most events were mild or moderate and temporary, often appearing during gradual dose increases. It can't assess a reader's current symptoms.
• Safety of Semaglutide. A review of the safety evidence, including digestive effects. The opening letter links it when introducing the possible burdens of treatment.
• Semaglutide in StatPearls. This reference explains how long semaglutide stays in the body and how little of the oral form reaches the blood. Oral means taken by mouth. The mechanism and dose letters use that background.

Product labels and FDA explanations

• Wegovy (semaglutide injection and tablets) prescribing information. The source for receptor activity, persistence and safety warnings, including the thyroid C-cell tumor findings in rodents and unknown risk in humans.
• Ozempic (semaglutide injection) prescribing information. The conversation list links this alongside the other product label so the exact preparation and approved use stay in view.
• FDA questions and answers about compounding. Explains why compounded medicines aren't FDA-approved and don't receive FDA review before being marketed.
• FDA alert about dosing errors with compounded injectable semaglutide. Explains the danger of measurement confusion. The dose letter discusses the problem without giving a calculation to copy.

P.S. “Does this source answer my question, or a different one?” I'd keep that beside any finding I wanted to take to an appointment.